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Abstract: Cancer is a multifactorial disease necessitating identification of novel targets for its treatment. Inhibition of Bcl-2 for triggered pro-apoptotic signaling is considered a promising strategy
for cancer treatment. Within the current work, we aimed to design and synthesize a new series of
benzimidazole- and indole-based derivatives as inhibitors of Bcl-2 protein. The market pan-Bcl-2
inhibitor, obatoclax, was the lead framework compound for adopted structural modifications. The
obatoclax’s pyrrolylmethine linker was replaced with straight alkylamine or carboxyhydrazine
methylene linkers providing the new compounds. This strategy permitted improved structural
flexibility of synthesized compounds adopting favored maneuvers for better fitting at the Bcl-2 major
hydrophobic pocket. Anti-cancer activity of the synthesized compounds was further investigated
through MTT-cytotoxic assay, cell cycle analysis, RT-PCR, ELISA and DNA fragmentation. Cytotoxic
results showed compounds 8a, 8b and 8c with promising cytotoxicity against MDA-MB-231/breast
cancer cells (IC50 = 12.69 ± 0.84 to 12.83 ± 3.50 µM), while 8a and 8c depicted noticeable activities
against A549/lung adenocarcinoma cells (IC50 = 23.05 ± 1.45 and 11.63 ± 2.57 µM, respectively). The
signaling Bcl-2 inhibition pathway was confirmed by molecular docking where significant docking
energies and interactions with key Bcl-2 pocket residues were depicted. Moreover, the top active
compound, 8b, showed significant upregulated expression levels of pro-apoptotic/anti-apoptotic of
genes; Bax, Bcl-2, caspase-3, -8, and -9 through RT-PCR assay. Improving the compound’s pharmaceutical profile was undertaken by introducing 8b within drug-solid/lipid nanoparticle formulation
prepared by hot melting homogenization technique and evaluated for encapsulation efficiency, particle size, and zeta potential. Significant improvement was seen at the compound’s cytotoxic activity.
In conclusion, 8b is introduced as a promising anti-cancer lead candidate that worth future finetuned lead optimization and development studies while exploring its potentiality through in-vivo
preclinical investigation.

This article is an open access article
distributed under the terms and
conditions of the Creative Commons

Keywords: Bcl-2 inhibitors; Indole-based analogues; benzimidazole; MTT cytotoxic assay; cell cycle
analysis; DNA fragmentation; ELISA; docking; solid/lipid nanoparticles
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1. Introduction
The failure of most cancer cells to undergo apoptosis confers them a survival advantage over normal cells. Apoptosis is a genetically programmed cell death to get rid of an
undesirable cell, which is necessary for cell turnover [1]. Apoptosis is controlled by two
major modes: the extrinsic and the intrinsic pathways. Both pathways lead to activation of
caspases that result in morphological changes such as chromatin condensation, nuclear
fragmentation, formation of apoptotic bodies and finally cell death [2].
The extrinsic pathway comprises external signals, that bind to the cell’s surface death
receptors resulting in the formation of the death-induced signaling complex [3]. Bcl-2
(B cell lymphoma gene 2) family proteins control the intrinsic pathway. These proteins
prevent the release of cytochrome C from mitochondria [4]. The Bcl-2 family of proteins
can be classified as proapoptotic and antiapoptotic proteins. The conserved Bcl-2 homology
domain-3 (BH3) of pro-apoptotic Bcl-2 members is responsible for the mitochondrial
apoptosis [5]. Anti-apoptotic Bcl-2 proteins have a hydrophobic groove, containing both
of the conserved Bcl-2 homology domains BH1 and BH2 which sequesters the BH3 of
pro-apoptotic Bcl-2 members [6].
There are three approaches for targeting Bcl-2 in cancer therapy. The first one depends
on the use of antisense oligonucleotide, which can bind to the complementary mRNA of
Bcl-2, resulting in blocking expression at the protein level. The second strategy develops
peptides against Bcl-2 protein [7,8]. Lastly, the third approach utilizes small molecules that
can bind to the hydrophobic groove of anti-apoptotic Bcl-2 [9]. These molecules target one
or more of P1–P4 sub-pockets in the BH3 groove of anti-apoptotic proteins. This binding
results in releasing pro-apoptotic BH3-only proteins that can activate Bax and Bak and lead
to apoptosis [10]. Several small molecules have been identified and synthesized, such as
venetoclax, disarib, and obatoclax (Figure 1).
Venetoclax is a highly potent BH3 mimetic molecule. It showed a subnanomolar
affinity to Bcl-2 (Ki < 0.010 nM) with no measurable affinities for other apoptotic proteins.
It showed cytotoxicity against non-Hodgkin’s lymphoma, chronic lymphocytic leukemia
(CLL) and acute leukemias [11]. Disarib is another selective Bcl-2 inhibitor [12]. Disarib
was proven to inhibit the growth of Bcl-2 high cancer cell lines and CLL patient primary cell
lines with minimum effect on Bcl-2 low cancer cell lines. In addition, disarib exhibited fewer
side effects in treated animals with respect to platelet count, body weight, and liver and
kidney functions [13]. Obatoclax is an oligopyrrole which antagonizes Bcl-2 and Bcl-xL [14].
Obatoclax binds to the BH3 domain of Bcl-2 and interrupts the interaction with proapoptotic
proteins. The combination of obatoclax and lapatinib, gifitinib, bortezomib, and entinostat
showed synergistic repression of cell growth in human breast cancer cells [15]. Furthermore,
obatoclax synergizes chemotherapeutic agents as cisplatin, in cancer cell lines [16].
For Bcl-2 inhibitors development, we have described several series of compounds
with chemical scaffolds that mimic obatoclax by either replacement of the pyrrole ring of
obatoclax with benzimidazole or extending the structure after the indole ring. Additionally,
comprehensive biological and molecular docking investigation, within the crystallised
Bcl-2 crystal structure, provided further insights regarding the molecular pro-apoptotic
mechanisms of the presented small synthesized molecules. Finally, formulating the most
promising lead within an optimized solid lipid nanoparticle formulation provided beneficial results concerning improved cytotoxic activity, drug release and pharmaceutical
properties, particularly drug’s aqueous solubility and bioavailability.
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spective affinities and binding interactions through molecular docking calculations [24].
Interestingly, the authors suggested anchoring of obatoclax just adjacent the hydrophobic
cleft (H1-3) which may compromise the drug’s ability to dissociate BH3-only pro-apoptotic
proteins for subsequent programmed cell death. Driven by the above findings, the presented study aimed for developing new pro-apoptotic agents, based on obatoclax principal
pharmacophore, with an extra goal of improved Bcl-2 hydrophobic cleft accommodation.
Obatoclax belongs to the class of organic compounds, designated as dipyrrins, incorporating two pyrrole rings within their chemical architectures where the two 5-membered
rings are being fused via a trivalent methine (-CH=) bridge. Here within the presented
manuscript, three structural modification strategies have been adopted to design the newly
synthesized compounds, Series-I-to-III (Figure 2). The first modification strategy was to
improve the obatoclax flexibility through replacing the drug’s central pyrrolylmethine
linker with straight alkylamine or carboxyhydrazine methylene linkers furnishing the
members of the Series-I or -II, respectively. The aim of such tactic was to permit enhanced
maneuver for these newly synthesized compounds to better accommodate the Bcl-2 major hydrophobic pockets (S1-to-5). Additionally, the terminal obatoclax pyrrole ring was
Pharmaceuticals 2021, 14, x FOR PEERreplaced
REVIEW with substituted phenyl groups to permit an enriched π–π stacking and other
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non-polar interactions with the hydrophobic residues at the Bcl-2 pocket.
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resulting in the members of Series-III. The latter members possess the double advent of
great flexibility and extended size. Finally, the adoption of the central pyrazole scaffold
was rationalized for its straightforward synthesis as well as easily derivatized during
the pyrazole ring closure. Based on the adopted three structural modification strategies,
fourteen compounds were synthesized as well as evaluated for respective predicted antiFigure 2 Rationalized design of the proposed
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The indole-based derivatives (Series-II and -III) were synthesized starting from the
commercially available indole-2-carboxylic acid (4) (Scheme 2). Throughout Fischer reaction, refluxing 4 with concentrated H2 SO4 and ethanol yielded the corresponding ethyl,1Hindole-2-carboxylate (5) [27]. Subsequent, condensation of the obtained ester intermediate
with hydrazine hydrate furnished the hydrazide key intermediate (6). Finally, Schiff’s base
condensation of 6 with different commercially available and synthesized aromatic aldehydes, under acidic conditions, provided the target hydrazone analogues (7a–d and 8a–f) [28].
Appearance of the characteristic methylene hydrogen at NMR spectra (δH = 8.16–8.98 ppm;
δC = 146.8–148.9 ppm) confirmed successful Schiff’s base formation. Preparation of several pyrazole-based aldehydes was proceeded through three-step chemical synthesis [29].
Synthesis of the pyrazole aldehydes, that served as the structural building blocks of the
Series-III compounds, was proceeded through initial acidic condensation of different ketones with phenylhydrazine derivatives yielded the corresponding imine analogues (10a–f)
(Scheme 3). Subsequently, Vilsmeier-Haack reaction, with the advent of phosphorous
oxychloride, provided the target pyrazole-based aldehydes (12a–f) exhibiting characteristic
NMR signals of CHO groups (δH = 9.97–10.00 ppm; δC = 185.1–185.3 ppm).
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were set as positive index comparators. Moreover, the safety profile of the synthesized
compounds was further investigated by examining their in-vitro cytotoxicity on
non-cancerous cell line; MDCK/kidney cells.
Findings within Figure 3A illustrate a dose-dependent impact of several synthesized
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tive index comparators. Moreover, the safety profile of the synthesized compounds was
further investigated by examining their in-vitro cytotoxicity on non-cancerous cell line;
MDCK/kidney cells.
Findings within Figure 3A illustrate a dose-dependent impact of several synthesized
compounds on MDA-MB-231/breast cell proliferation. Rising drug concentration was
directly related with elevated cell growth inhibition up to the highest applied concentration
(100 µM) (p < 0.05). Interestingly, most of the tested compounds had a dose dependent
cytotoxicity or a plateau effect, except for compound 3c on MDA-MB-231/breast cancer
where it enhanced cell proliferation at 100 µM drug concentration. The steepest decline
within the cell proliferation was seen with 7c,d and 8a–d reaching down to very low % cell
viabilities (12% and 14%) at 100 µM concentrations. The latter suggests great susceptibility
of MDA-MB-231/breast cancer cells towards indole derivatives, particularly those having
pyrazole-based scaffolds (Series-III). The rest of compounds exhibited comparable cytotoxicity patterns as those for positive reference controls, 5-FU and DOX, since minor %viability
fluctuations were depicted across the applied drug concentrations. Regarding the drug’s
impact on A549/lung adenocarcinoma cell proliferation, both investigated and positive
control compounds showed quite lower overall anticancer activity as compared to their
actions up on the MDA-MB-231/breast cancer cells. Nevertheless, comparable differential
activity profiles were depicted among the investigated compounds, where compounds 8a–c
exhibited the highest activity profiles with steepest decrease in % cell viability (70–79%;
p < 0.001) at 100 µM concentrations (Figure 3B). This again suggests promising anticancer
activity of the indole-based compounds on A549/lung cancer cells, particularly for the
ones incorporating the pyrazole scaffolds. The rest of the compounds exhibited comparable
pattern of cell growth inhibition across their concentration range which was also quite
similar to that of positive control drugs. However, it was only for compound 3b where its
anticancer activity on A549/lung cancer cells depicted irregular effects with tendency to
increase the cell proliferation. Evaluating drug’s cytotoxicity on non-cancerous kidney cells,
Figure 3C showed higher safety profiles for synthesized compounds compared to controls,
5-FU and DOX. Significantly higher vitality patterns were illustrated for all compounds,
particularity over the concentration range 0.1–10 µM, as compared to those of reference
compounds (p < 0.001).
For gaining more insights about the efficacy/safety profiles of the synthesized compounds, IC50 values for promising cytotoxic compounds were estimated over the three
cell lines. Only compounds exhibiting significant cytotoxicity, with cut-off value < 85%
vitality at 100 µM on both cancerous cell lines, were considered relevant for IC50 estimating
and warrant further consideration. Interestingly, the selected compounds for MDA-MB231/breast cancer cells (3a, 7b, 7d, and 8a–d) illustrated relevant IC50 values reaching
down to two-digit micromolar activity (Table 1). Members of Series-III showed the lowest IC50 (down to 12.69 µM) suggesting the preferential cytotoxicity of their substituted
pyrazole arms. Both 8d and 8f showed higher IC50 (21.64 and 31.46 µM, respectively)
suggesting activity preferentiality for aromatic substitution, at C3 pyrazole ring, while
tolerating small-sized aliphatic chains. Compound 7d was comparable to the top-active
members of Series-III with IC50 17.38 µM, suggesting Series-II preferentiality for pyridine
ring substitution over methoxy phenyl synthon. Regarding IC50 on MDA-MB-231/lung
adenocarcinoma, only 8b and 8c were evaluated suggesting preferential activity for pyrazole substitution with branched aliphatic chains. Finally, the IC50 for selected Series-III
compounds on non-cancerous/kidney cells were much higher than the other two Series,
reaching up to IC50 92 µM activity for 8b. Based on all the above findings, significant
cytotoxic activity has been assigned for members of Series-III which were also presented
with high safety profile, particularly 8b, on non-cancerous cell line. Therefore, compound
8b was considered promising with double the benefits of high efficacy/safety profiles
making it worthy of further investigations.

Pharmaceuticals 2021, 14, 113

However, it was only for compound 3b where its anticancer activity on A549/lung cancer
cells depicted irregular effects with tendency to increase the cell proliferation. Evaluating
drug’s cytotoxicity on non-cancerous kidney cells, Figure 3C showed higher safety profiles for synthesized compounds compared to controls, 5-FU and DOX. Significantly
higher vitality patterns were illustrated for all compounds, particularity over the 8conof 37
centration range 0.1–10 µM, as compared to those of reference compounds (p < 0.001).
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Figure 3. In-vitro cytotoxicity of the fourteen final synthesized compounds on cancerous and non-cancerous cell lines.
(A)
MDA-MB-231/breast
cancer
cells;
(B) A549/lung
adenocarcinoma
cells;
MDCK/kidney
non-cancerous
cells. (A)
At
Figure
3. In-vitro cytotoxicity
of the
fourteen
final synthesized
compounds
on(C)
cancerous
and non-cancerous
cell lines.
1MDA-MB-231/breast
× 104 cells/well cell cancer
density,
cells
were
treated
with
several
drug
concentrations
(0.1,
1,
10,
and
100
µM)
of
investigated
cells; (B) A549/lung adenocarcinoma cells; (C) MDCK/kidney non-cancerous cells. At 1 × 104
compounds
or
positive
comparator;
5-FUwith
and DOX,
48 hconcentrations
exposure time.(0.1,
Cytotoxicity
via MTT-based
cells/well cell density, cells were treated
severalfor
drug
1, 10, andwas
100 identified
µM) of investigated
comcolorimetric
assay
(490
nm)
and
%
cell
growth
viability
was
estimated
in
triplicates
as
compared
to
vehicle
negative
controls
pounds or positive comparator; 5-FU and DOX, for 48 h exposure time. Cytotoxicity was identified via MTT-based
colorimetric assay
nm) and
% cell
was estimated
in triplicates as compared to vehicle negative controls
representing
the(490
untreated
cells.
Bluegrowth
dottedviability
line indicates
this control.
representing the untreated cells. Blue dotted line indicates this control.

For gaining more insights about the efficacy/safety profiles of the synthesized
compounds, IC50 values for promising cytotoxic compounds were estimated over the
three cell lines. Only compounds exhibiting significant cytotoxicity, with cut-off value <
85% vitality at 100 µM on both cancerous cell lines, were considered relevant for IC50 es-
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Table 1. In-vitro a data of MTT-cell proliferation assay for promising synthesized compounds on
both cancerous and non-cancerous cell lines.

Compound b

MDA-MB-231

A549

MDCK

29.68 ± 4.03

ND

43.77 ± 1.09
MDA-MB-231
c
IC17.38
50 (µM)
± 3.23

ND
A549
c
IC50 (µM)
ND

ND
28.92
± 1.49
MDCK
c
IC50 (µM)
ND
73.86
ND± 2.30
28.92
92.75±±1.49
0.43
ND± 3.00
87.29
73.86 ± 2.30
92.75 ND
± 0.43
87.29 ND
± 3.00

Table 1. In-vitro a data of MTT-cell proliferation
assay for promising csynthesized compounds
on
No.
IC50 (µM) c
IC50 (µM)
IC50 (µM) c
both cancerous and non-cancerous cell lines.

3a

b
b7
Compound
No.
7d

a8
3a

12.69
± 0.84
29.68
± 4.03
NDND
43.77
± 1.09
ND ± 1.45
12.71
± 2.48
23.05
17.38
± 3.23
ND ± 2.57
12.83
± 3.50
11.63
12.69 ± 0.84
ND
31.46
± 4.66
12.71
± 2.48
23.05 ±ND
1.45
21.64
± 0.28
12.83
± 3.50
11.63 ±ND
2.57
a In-vitro data
8d are reported as mean
31.46of
± three
4.66 independent experiments
ND
ND
± SEM; b Tested
compounds
21.64<±85%,
0.28on both cancerous
ND
ND 100 µM
were those 8f
depicted % cell viability
cell lines, at their respective
a In-vitro data arecreported
concentrations;
IC50 values
represent
concentration
molecule
being
capaas mean
of threeeffective
independent
experimentsof±given
SEM; bsmall
Tested
compounds
were
those
c
ble
of
inducing
50%
inhibitory
response
of
its
own
intrinsic
maximum
response
following
48
h of
depicted % cell viability < 85%, on both cancerous cell lines, at their respective 100 µM concentrations; IC50 values
drug
exposure;
= Not-detected.
represent
effectiveND
concentration
of given small molecule being capable of inducing 50% inhibitory response of its
7b
8b
7d
8c
8a
8d
8b
8f
8c

own intrinsic maximum response following 48 h of drug exposure; ND = Not-detected.

2.3.2. Morphological Assessment
2.3.2.The
Morphological
Assessment
impact of 8b
on cancerous cellular morphology was evaluated over different
concentrations
following
h exposure
time. In
MDA-MB-231/breast
cancerover
cells,different
normal
The impact of 8b on48cancerous
cellular
morphology
was evaluated
membrane
integrity
and control
group nucleus
was depicted
forcells,
cellsnormal
within
concentrations
following
48 h exposure
time. In morphology
MDA-MB-231/breast
cancer
vehicle
negative
control
group group
(Figurenucleus
4A). Contrarily,
cells
treated
with
exhibited
membrane
integrity
and control
morphology
was
depicted
for8b
cells
within
significant
cell morphology
intercellular
dilatation,
andexhibited
cellular
vehicle
negative
control groupalteration,
(Figure 4A).
Contrarily, space
cells treated
with 8b
shrinkage
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proceeded
within
a dose-dependent
manner
as escasignificant (Figure
cell morphology
alteration,
intercellular
space
dilatation, and cellular
shrinkage
(Figure
4B).concentrations
Alterations proceeded
within
a dose-dependent
manner
as escalated
lated drug
showed cells
being
gradually shrunken,
unable
to adhere drug
well,
concentrations
showed
cells
being
gradually
shrunken,
unable
to
adhere
well,
floated,
floated, and clustered together (Figure 4C,D). At 100 µM concentration, the cell number
and clustered
4C,D).
µM polyhedral
concentration,
thewas
cell observed
number became
became
highlytogether
declined(Figure
and great
lossAt
of 100
cellular
shape
as cells
highly declined
and great
loss of cellular morphology
polyhedral shape
was 4E).
observed
cells acquired
acquired
the tentacled
spindle-shaped
(Figure
Theseasmorphological
the tentacled
morphology
(Figure 4E).
These
changes were
changes
werespindle-shaped
more drastic with
8b as compared
to 5-FU
formorphological
similar concentrations
(100
more(Figure
drastic with
8b as compared
5-FU for similar
concentrations
(100 µM)
4F).
µM)
4F). Comparable
celltomorphology
changes
were observed
with(Figure
A549/lung
Comparable
cell
morphology
changes
were
observed
with
A549/lung
adenocarcinoma
adenocarcinoma (Figure 5A–E). Nevertheless, an epithelial-mesenchymal transition was
(Figure
5A–E).
Nevertheless,
epithelial-mesenchymal
transition
was observed
within
observed
within
5-FU group, an
rather
than 8b, at same drug
concentration
(100 µM)
(Fig5-FU
group,
rather
than
8b,
at
same
drug
concentration
(100
µM)
(Figure
5F).
The
ure 5F). The later finding presents a significant advantage for 8b as it did not triggerlater
this
finding presents a significant
advantage program
for 8b asconferring
it did not trigger
thisproperties
evolutionarilyevolutionarily-conserved
developmental
metastatic
upon
conserved developmental
program conferring
metastaticand
properties
upon
cancerous
cells
cancerous
cells through enhanced
mobility, invasion,
apoptotic
stimuli
resistance
through
enhanced
mobility,
invasion,
and
apoptotic
stimuli
resistance
[31].
[31].
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2.3.3.
2.3.3. Apoptosis
Apoptosis Rate
Rate and
and Cell
Cell Cycle
Cycle Analysis
Analysis
Further
investigation
ofmechanistic
8b mechanistic
growth action
inhibitory
action on
Further investigation
of 8b
growth inhibitory
on MDA-MB-231/
MDA-MB-231/breast
cancer,
both
cell
cycle,
and
apoptosis
rate
analysis
were
conducted
breast cancer, both cell cycle, and apoptosis rate analysis were conducted at the compound’s
50
value
(13
µM).
Using
flow
cytometry,
at
the
compound’s
approximated
IC
approximated IC50 value (13 µM). Using flow cytometry, apoptosis rate analysisapoptosis
was prorate
analysis
was
proceeded
through
staining the cell
surface-translocating
phosphaticeeded
through
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the cell
surface-translocating
phosphatidylserine
with Annexin-V
dylserine
Annexin-V
fluorescent conjugate,
the calcium-dependent
phospholipid
fluorescentwith
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the calcium-dependent
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binding protein [32].
However,
binding
[32].
However,
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analysis was
achieved
usingdye
propidium
iodine
cell cycleprotein
analysis
was
achievedcell
using
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iodine
fluorescent
to stoichiometfluorescent
stoichiometrically
stainquantitation
cell DNA contents
allowing quantitation
and
rically staindye
cell to
DNA
contents allowing
and identification
of all cell phase
identification
cell phase
rates; G0-G1,
G2/M,
and pre-G1
[33,34].
The impact
of 8b
rates; G0-G1, of
S, all
G2/M,
and pre-G1
[33,34].S, The
impact
of 8b on
cell cycle
distribution
on
cell cycle
distribution
predominant
cell population
at G2/M
stage (25.32%)
depicted
predominant
celldepicted
population
at G2/M stage
(25.32%) was
significantly
higher
was
significantly
higher
than
that
of
untreated
cell
line
(6.15%;
p
<
0.001)
(Figure
6A).
The
than that of untreated cell line (6.15%; p < 0.001) (Figure 6A). The elevated cell population
elevated
at G2/M by
stage
was complemented
by significant
at
at G2/M cell
stagepopulation
was complemented
significant
reduction at pre-G1
stage ofreduction
treated cells
pre-G1
stage to
of negative
treated cells
as compared
negative
controls
vs. 18.93%;
as compared
controls
(1.72% vs.to18.93%;
Figure
6B).(1.72%
For identifying
theFigure
mode
6B).
Fordeath
identifying
the mode
cell death
promoted by 8b within
of cell
promoted
by 8b of
within
MDA-MB-231/breast
cancer MDA-MB-231/breast
cells, apoptosis rate
analysis
wasapoptosis
performed
following
h exposure
time.
Compound
8b (13 µM)
induced
cancer
cells,
rate
analysis48
was
performed
following
48 h exposure
time.
Comboth early
late stages
of apoptosis
in and
breast
cancer
cellofline
with significantly
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%
pound
8b and
(13 µM)
induced
both early
late
stages
apoptosis
in breast cancer
cell
apoptotic
cell
levels
as
compared
to
controls
(p
<
0.01
and
p
<
0.001,
respectively)
(Figure
7).
line with significantly elevated % apoptotic cell levels as compared to controls (p < 0.01
Moreover,
the respectively)
average proportion
positive
cells (total
apoptotic
and
p < 0.001,
(Figure of
7).Annexin-V
Moreover, stained
the average
proportion
of Annexin-V
cells) elevated
within untreated
cells tofrom
18.93%
in within
treateduntreated
ones (p <cells
0.001).
stained
positivefrom
cells 1.72%
(total apoptotic
cells) elevated
1.72%
to
Interestingly,
compound
no influence on
the necrosis
of MDA-MB-231/breast
18.93%
in treated
ones (p8b
< showed
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compound
8b showed
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the necrosis of MDA-MB-231/breast cancer cells. The above provided findings are sup-
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Figure 6. Impact of compound 8b upon cell cycle distribution within MDA-MB-231/breast cancer cell line. Following

Figure 6. Impact of compound 8b upon cell cycle distribution within MDA-MB-231/breast cancer cell line. Following 48
48 h-period incubation of cells with either 8b (13 µM; approximated IC50 ) or vehicle negative control [0.1% DMSO (v/v)],
h-period incubation of cells with either 8b (13 µM; approximated IC50) or vehicle
negative control [0.1% DMSO (v/v)], cells
cells were fixed, stained with propidium iodide (PI), and assessed via flow cytometry; (A) DNA histograms for cell cycle
were fixed, stained with propidium iodide (PI), and assessed via flow cytometry; (A) DNA histograms for cell cycle disdistribution of untreated cells (left panel) and 8b group (right panel) at in 2N (G0G1), >2N (S), 4N (G2/M), and <2N (pretribution
of untreated cells (left panel) and 8b group (right panel) at in 2N (G0G1), >2N (S), 4N (G2/M), and <2N (pre-G1),
® software; (B) Bar-chart
cellwas
number
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using CellQuest
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three independent experiments ± SEM. Statistical analysis was performed using Student-t-test (***, p < 0.001).
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2.3.4.
DNA Fragmentation
2.3.4. DNA
Fragmentation Determination
Determination
In
order
to
delineate
In order to delineate the
the mechanistic
mechanistic aspects
aspects of
ofMDA-MB-231/breast
MDA-MB-231/breast cancer
cancer cell
cell
death
death mediated
mediated by
by 8b,
8b, the
the DNA
DNA fragmentation
fragmentation assay
assay was
was conducted
conducted as
as being
being highly
highly
characteristic for apoptosis. Significant DNA fragmentation was depicted with 8b at IC50
characteristic for apoptosis. Significant DNA fragmentation was depicted with 8b at IC50
doses (13 µM) at various time-intervals; 48 h and 72 h following cell treatments. A typical
doses (13 µM) at various time-intervals; 48 h and 72 h following cell treatments. A typical
ladder pattern of internucleosomal fragmentation was observed from cell homogenates
ladder pattern of internucleosomal fragmentation was observed from cell homogenates
within both incubation periods (Figure 8). Such findings further confirm the significant
within both incubation periods (Figure 8). Such findings further confirm the significant
activity of 8b as a potent inducer of apoptosis.
activity of 8b as a potent inducer of apoptosis.
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Figure 8. DNA fragmentation of MDA-MB-231/breast cancer cell line treated with 8b. Fragmenta-

tions of 8.
genomic
DNA
in breast cancer cells
treated with 8b (13 µM) for cancer
48 or 72 h cell
exposure
Figure
DNA
fragmentation
ofwere
MDA-MB-231/breast
line treat
time. Low-molecular-weight DNA from homogenized cells was resolved and visualized on ethidium
tions of genomic DNA in breast cancer cells were treated with 8b (13 µM)
bromide-stained 1.5% agarose gel while being photographed by UV-illumination electrophoresis;
time.
Low-molecular-weight
DNA from homogenized cells was resolved a
C = DMSO
vehicle control.
idium
bromide-stained 1.5% agarose gel while being photographed by UV
2.3.5. Apoptotic Gene Expression and Protein Level Analysis
phoresis;
C = DMSO
vehiclestrong
control.
Compound
8b demonstrated
cytotoxic impact upon breast cancer cell lines,

as it accomplished significantly low IC50 value (12.71 µM) with confirmed apoptosis
induction. Dissection of the compound’s proapoptotic activity was proceeded through gene
2.3.5.
Apoptotic
Gene
Expression
and Protein
Level
expression
analysis for
key genes,
controlling apoptosis
pathway, as
well asAnalysis
protein level
determination. Following 8b treatment for 48 h, alterations within MDA-MB-231/breast
Compound 8b demonstrated strong cytotoxic impact upon b
cancer cell expression of Bcl-2, Bax, caspase-3, -8, and -9 genes, as well as cytochrome c
β-tubulin proteins
levels were determined
real-time
polymerase
chain
50 value
(12.71
µM)
with co
asand
it class-III
accomplished
significantly
low ICusing
reaction (RT-PCR) or ELISA technique, respectively. Typically, Bcl-2, Bax, caspases, and
duction.
Dissection of the compound’s proapoptotic activity wa
cytochrome c proteins contributes within the regulation of apoptotic signaling. Acting as
apoptotic
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(Bcl-2),
thegenes,
Bcl-2 family
proteins play their
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gene
expression
analysis
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controlling
apoptosis
role in apoptosis [35]. The caspases family are cysteine proteases being classified as either
level
determination.
8band -9treatment
for 48 h,
executioners;
caspase-3, -6, or -7 orFollowing
initiators; caspase-8
[36]. Regrading caspase-8,
its activation is proceeded through
extrinsic
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dependent
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pathway,
MDA-MB-231/breast
cancer
cell
expression
of Bcl-2,
caspase-3
while, caspase-9 activation is within the event of intrinsic mitochondrial cytochrome
well
as cytochrome
c participation
and class-III
β-tubulin
levels
c leakage
[37]. Additionally,
of activated
caspase-3proteins
is to be essential
for were
caspase-8polymerase
activation [38]. Class-III
are pure
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within
cancer
al-time
chainβ-tubulin
reaction
(RT-PCR)
or ELISA
technique,
r
patients being associated with aggressive phenotypic/drug-resistant cancers and part of
Bcl-2,
Bax,pro-survival
caspases,
andpathway,
cytochrome
c proteins
contributes
wit
complicated
molecular
being triggered
via poor nutrient
supply and
hypoxia [39].signaling. Acting as apoptotic activator (Bax) or inhib
apoptotic
Findings within Figure 9A illustrated strong stimulated expression of pro-apoptotic
family
proteins
theirgenes;
significant
role
in Caspase-8
apoptosis
[35].andThe ca
BAX gene
(3.61 folds),play
and apoptotic
Caspase-3 (4.28
folds),
(1.53 folds),
Caspase-9
(7.65 folds) as
compared
to negative controls
(p < 0.05executioners;
and p < 0.001). Nevertheless,
teine
proteases
being
classified
as either
caspase-3,
significant downregulation of anti-apoptotic gene Bcl-2 (0.165 folds) was depicted and have
caspase-8
and
[36].Bax/Bcl
Regrading
activation
is procee
been translated
into-9
elevated
expression caspase-8,
ratio (1 → 21.88;its
p < 0.001).
The Bax/Bcl-2
gene expression ratio can serve as early predictor for cancer in patients as well as sensitive
death-receptor
dependent apoptotic pathway, while, caspase-9 ac
monitor of cancer progression [40]. On the other hand, compound 8b illustrated increased

event of intrinsic mitochondrial cytochrome c leakage [37]. Additio
activated caspase-3 is to be essential for caspase-8 activation [38].
pure prognostic biomarker within cancer patients being associ
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levels of the apoptotic stimulator cytochrome c (0.675 ng/mL vs. 0.295 ng/mL; p < 0.01)
and down-regulated levels of class-III β-tubulin (0.23 vs. 0.73 ng/mL; 68.36% inhibition;
p < 0.001) as compared to controls (Figure 9B). Gathering up all the provided evidence,
up-regulation of Caspase-3, -8, -9 and Bax, while down-regulation of Bcl-2 genes and class-III
Pharmaceuticals 2021, 14, x FOR PEER REVIEW
16 of 39
β-tubulins are suggested believed to be related to compound 8b-induced apoptosis within
breast cancer cell line.
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Figure 9. Apoptotic gene expressions and protein level analysis of MDA-MB-231/breast cancer cells exposed to 8b.
Figure
9. Apoptotic
gene expressions and protein
levelBax,
analysis
MDA-MB-231/breast
cells
exposed
to 8b. (A)
(A) Expression
of pro-apoptotic/anti-apoptotic
of genes;
Bcl-2, of
caspase-3,
-8, and -9 usingcancer
RT-PCR
method;
(B) Evaluation
Expression
of
pro-apoptotic/anti-apoptotic
of
genes;
Bax,
Bcl-2,
caspase-3,
-8,
and
-9
using
RT-PCR
method;
(B)
Evaluation
of cytochrome c and class-III β-tubulin protein levels in MDA-MB-231/breast cancer cells using ELISA technique. Within
of
cytochrome
c and class-III
β-tubulin proteincancer
levels cells
in MDA-MB-231/breast
cancer
ELISA technique.
Within
both
assays, cultivated
MDA-MB-231/breast
were treated with 8b
at itscells
IC50using
concentration
(13 µM) for
48 h
both assays, cultivated MDA-MB-231/breast cancer cells were treated with 8b at its IC50 concentration (13 µM) for 48 h
exposure period. All data are represented as average of three independent experiments ± SEM. Statistical analysis was
exposure period. All data are represented as average of three independent experiments ± SEM. Statistical analysis was
performed using Student-t-test (*, p < 0.05; ***, p < 0.001).
performed using Student-t-test (*, p < 0.05; ***, p < 0.001).

2.4. Computational Study
2.4. Computational Study
To gain more insights about differential cytotoxic activity of synthesized compounds,
To gain more insights about differential cytotoxic activity of synthesized commolecular docking simulations were conducted for all agents. The binary complex of X-ray
pounds, molecular docking simulations were conducted for all agents. The binary comcrystallized Bcl-2 (PDB ID: 6qgk; resolution 1.80 Å) [41], bounded to tetrahydroisoquinolineplex of X-ray crystallized Bcl-2 (PDB ID: 6qgk; resolution 1.80 Å) [41], bounded to tetraphenyl pyrazole derivative, was adopted for the docking studies. Adopting such complex
hydroisoquinoline-phenyl pyrazole derivative, was adopted for the docking studies.
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ligand with the synthesized compounds as well as its extended orientation within the
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tocol was achieved through redocking the crystallized ligand (PDB ID: J1Q) showing a
root-mean standard deviation (RMSD) below 2 Å. Depicting RMSD values below 2 Å
indicates that both the adopted algorithms and parameters were sufficient for determining the best docking pose [42]. Regarding the docking results of the top cytotoxic drugs,
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limited binding of the Series-I compound (3b) towards Bcl-2 pockets was illustrated. The
benzimidazole-based ligand adopted V-shaped conformation with limited binding to P2
and P3 hydrophobic pockets. The benzimidazole scaffold predicted relevant anchoring
within P3 through H-bonding with Asp111, while the substituted phenyl group finely overlaid at P2 pocket (Figure 11A). This orientation was further stabilized through π-π stacking
of the benzimidazole ring with Tyr108 (Supplementary Materials; Table S1). More extended
orientations were depicted for the Series-II indole derivatives (7a and 7b). Binding was extended at P2 through P4 sub-pockets showing their indole rings being docked at P2. Higher
docking score was assigned for 7d (S = −4.8585 Kcal/mol vs. −4.76959 Kcal/mol for 7b),
where double polar interactions between its pyridine ring and Arg146 side chain justified
significant anchoring within pocket P4 (Figure 11B). Moreover, the pyridine ring was
further stabilized through double π-hydrogen interaction with Leu137 of P4 subsite suggesting its great affinity to Bcl-2 protein. Owing to its amide linker flexibility, 7d indole ring
showed better overlay with the crystallized ligand than does the 3a benzimidazole scaffold.
For the pyrazole-based Series-III ligands, comparable binding modes, to the crystallized ligand, were suggested (RMSD = 1.211 to 1.7374 Å) owing to a similar topology
of central pyrazole with substituted aromatic arms. Extended orientations and conformations over P1-P4, with much closer proximity towards P5 subsite, have been predicted for Series-III ligands. Compound 8b showed one of the highest docking scores
(S = −6.1846 Kcal/mol), which was explained by its exhibiting significant hydrogen bonding between its amide linker and Arg146 side chain at P4 subsite (Figure 10C). The same
polar interaction was predicted for the other Series-III members confirming their superior
Bcl-2 affinity (S = −5.7070 to −6.2460 Kcal/mol) and the importance of Arg146 in ligand
binding. Notably, compound 8f was suggested with the lowest member docking score
(S = −4.9429 Kcal/mol) for lacking contacts with P1 due to its short methyl arm instead
of the substituted aromatic side chain in all Series-III members. Additionally, the 5-chloro
Pharmaceuticals 2021, 14, x FOR PEER REVIEW
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Proceeding throughout the docking studies, validation of the adopted docking
protocol was achieved through redocking the crystallized ligand (PDB ID: J1Q) showing
a root-mean standard deviation (RMSD) below 2 Å. Depicting RMSD values below 2 Å
indicates that both the adopted algorithms and parameters were sufficient for determining the best docking pose [42]. Regarding the docking results of the top cytotoxic
drugs, limited binding of the Series-I compound (3b) towards Bcl-2 pockets was illus-
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stituent on the pyrazole ring exhibited great solvent exposure suggesting high solvation
penalty (Figure 10D).
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2.5. Solid Lipid Nanoparticle Formulation Studies
In an attempt to the clinical suitability of 8b, the in-silico pharmacokinetic properties and drug-likeness of compound was investigated using free web-based tool SwissADME (http://www.swissadme.ch/). Notably, the predicted poor water-solubility of 8b
(LogS_SILICOS-IT = −7.62; 1.06 × 10−5 mg/mL; 2.38 × 10−8 mol/L) was identified as a
significant parameter that might hinder the compound’s full potential cytotoxic activity.
Thus, Solid lipid nanoparticles (SLNs) formulation was adopted as a simple cost-effective
approach for optimizing the compound’s kinetic parameters. The main target of SLNs is to
enhance the drug absorption, enhance the pharmacological response, and decrease the side
effects. SLNs are colloidal dispersions made of solid lipid (possessing high melting point)
and a hydrophilic surfactant [43]. SLNs are considered a new generation of submicronsized lipid emulsions where solid lipids are utilized instead of liquid lipids (oil) [44]. Due
to their unique characteristics, such as small size, large surface area, and increased drug
loading capacity, SLNs are attracting great attention of formulators world-wide to improve
performance and bioavailability of pharmaceuticals [45]. It was reported that SLNs have
the ability to release entrapped drug in controlled manner and enhance stability of the
entrapped drug [46]. Therefore, formulating 8b as SLNs was expected to enhance its
bioavailability at the tumor site and hence improve its cytotoxic activity.
2.5.1. Design, Preparation and Optimization of Drug-SLN
Eight drug-SLNs formulations were prepared via hot-melting homogenization technique. The formulations were designed by 23 -factorial design using Stat-Ease® V.11 software (Design-ExpertTM ; Minneapolis, MN, USA) (Table 2). The selected factors (independent variables) were type of lipid (A; X1 ) and Surfactant (B; X2 ), as well as the concentration
of surfactant (C; X3 ). According to the adopted 23 -factorial design, eight formulations were
prepared and evaluated for encapsulation efficiency (Y1 : EE%), particle size (Y2 : PS) and
zeta potential (Y3 : ZP). Compositions of eight drug-SLNs formulations are presented in
Table 3. Drug analysis at different concentration was done using HPLC at λmax 254 nm,
showing linear relationship between the drug concentration and peak area, obeying BeerLambert’s law (R2 = 0.999) (Supplementary Materials; Figure S1).
Table 2. The formulation factors and responses of 23 factorial design for drug-solid lipid nanoparticles (SLNs).
Factors and Responses

Level Used

Factor

Name

Low (−1)

High (+1)

A: X1
B: X2
C: X3

Type of lipid
Type of surfactant
Surfactant conc. (% w/v)

Compritol 888 ATO (COMP)
Cremophor RH40
1%

Glyceryl Monostearate (GMS)
Poloxamer 188
1.5%

Response

Name

Goal

Y1
Y2
Y3

EE (%)
PS (nm)
ZP (mV)

Maximize
Minimize
Maximize

Table 3. The eight designed drug-SLNs according to 23 -factorial design.
SNP Formulation No.
1
2
3
4
5
6
7
8

X1

X2

X3

A: Lipid Type

B: Surfactant Lipid

C: Surfactant Conc. (% w/v)

COMP
COMP
COMP
GMS
COMP
GMS
GMS
GMS

Cremophor RH40
Cremophor RH40
Poloxamer 188
Cremophor RH40
Poloxamer 188
Cremophor RH40
Poloxamer 188
Poloxamer 188

1.5
1
1
1
1.5
1.5
1
1.5
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2.5.2. The Effect of Formulation Factors in the Responses
The prepared formulations of drug-SLNs were evaluated for the preselected responses;
Encapsulation Efficiency (Y1: EE%), the particle size (Y2: PS) and zeta potential (Y3: ZP).
As represented in Table 4, it was found that there was a difference in the results of the
responses which gave an indication that the formulation factors have a great effect of
the responses.
Table 4. The measured responses of prepared drug-SLNs according to 23 factorial design.
SNP Formulation
No.

(Y1)
EE%

(Y2)
PS (nm)

(Y3)
ZP (mV)

Polydispersity
Index (PDI)

F1
F2
F3
F4
F5
F6
F7
F8

37.1 ± 2.45
53.4 ± 1.65
95.3 ± 1.34
82.8 ± 2.55
86.8 ± 3.32
67.7 ± 1.52
94.6 ± 2.67
92.8 ± 2.38

140.9 ± 3.2
135.1 ± 1.0
329.4 ± 6.1
189.8 ± 3.3
181.5 ± 2.1
100.4 ± 0.4
537.3 ± 10.4
226.1 ±10.5

−12.3 ± 0.77
−13.6 ± 0.32
−21.7 ± 0.15
−36.1 ± 1.90
−16.4 ± 1.10
−39.4 ± 0.095
−37.5 ± 0.58
−29.3 ± 1.17

0.352 ± 0.03
0.282 ± 0.01
0.563 ± 0.03
0.432 ± 0.04
0.442 ± 0.02
0.433 ± 0.01
0.582 ± 0.04
0.639 ± 0.12

With the prepared formulations of drug-SLNs, significant impact on the preselected
responses was depicted in response to the formulation factors. The EE% of all prepared
drug-SLNs ranged from 37.1 ± 2.45% for F1 to 95.3 ± 1.34% for F3. As represented by
model Equation (1), the EE% was increased by increasing the level of X1 and X2 from −1
to +1. These results infer that the formulations prepared by GMS and Poloxamer 188 had
a higher EE% than those prepared using COMP or Cremophor RH40. Moreover, EE%
showed an inverse relationship with X3: surfactant concentration where higher EE% was
seen with 1.5% w/v surfactant.
Y1 (EE%) = 76.31 + 8.16 X1 + 16.06 X2 − 5.21 X3

(1)

For better illustration, a 3D-response surface plot showing the impact of formulation
factors on EE% was constructed (Figure 12). Interestingly, GMS-prepared SLNs exhibited higher EE% than those constituted by COMP. These findings might be for the large
encapsulation space in case of GMS resulting from less-ordered SLNs structure by the
virtue of their long carbon chains (C21) [10,30]. Additionally, higher EE% was assigned
for Poloxamer 188-prepared SLNs as compared to Cremophor RH40 which may be correlated to the higher hydrophilic-lipophilic balance (HLB) value proposed by Poloxamer
188 [47]. Latter findings are in good agreement with Qushawy et al., where the prepared
carbamazepine-SLNs depicted increased EE% through using GMS and Poloxamer 188
as solid lipid and surfactant, respectively [48]. The increase of surfactant concentration
from 1% to 1.5% resulted in decreased EE% which may be for increased drug solubility
within the aqueous phase [49]. The same results were depicted by Joseph et al. where
olanzapine-SLNs EE% showed an inverse relationship with surfactant concentration [50].
Regarding the PS of all prepared drug-SLNs, values ranged from 135.1 ± 1.0 nm for
F2 to 537.3 ± 10.4 nm for F7. The model Equation (2) of PS, revealed that PS had a direct
relationship with X1 and X2 while, an inverse relationship with X3. As shown by Figure 13,
the 3D response surface plot studied the impact of formulation factors (X1, X2 and X3) on
PS of the prepared SLNs. It was found that PS was increased in case of CMS than in case of
COMP which might be correlated to the fact of using solid lipid with high melting point,
resulted in slow crystallization and large particle size [51]. The results in good agreement
with Priyanka and Hasan found that the particle size of prepared montelukast SLNs was
influenced by lipid type and the decreasing order of particle size for the three lipids was
Compritol < GMS < stearic acid [52].
Y2 (PS) = 250.06 + 33.34 X1 + 88.51 X2 − 67.84 X3

(2)
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Regarding the PS of all prepared drug-SLNs, values ranged from 135.1 ± 1.0 nm for
F2 to 537.3 ± 10.4 nm for F7. The model Equation (2) of PS, revealed that PS had a direct
relationship with X1 and X2 while, an inverse relationship with X3. As shown by Figure
13, the 3D response surface plot studied the impact of formulation factors (X1, X2 and X3)
on PS of the prepared SLNs. It was found that PS was increased in case of CMS than in
case of COMP which might be correlated to the fact of using solid lipid with high melting
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The PS of the prepared SLNs was also affected by surfactant type, where using
Poloxamer 188 resulted in SLNs larger sizes than those prepared by Cremophor RH40.
This may be reasoned to the conception of using surfactant with higher HLB can result in
preparation of SLNs with larger size [53]. Additionally, as the surfactant concentration
elevated from 1% to 1.5%, the particle size of SLNs decreased. This might be assigned21toof 37
reduction within interfacial tension between the emulsion phases by increasing the concentration of surfactant which led to smaller PS of SLNs after congealing [50,52].
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Moving towards the final parameter, The ZP of all prepared drug-SLNs was ranged
from −12.3 ± 0.77 mV for F1 to -39.4 ± 0.095 mV for F6. zeta potential (ZP) is defined as
potential difference existing within the stationary layer between the dispersion medium
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The PS of the prepared SLNs was also affected by surfactant type, where using
Poloxamer 188 resulted in SLNs larger sizes than those prepared by Cremophor RH40.
This may be reasoned to the conception of using surfactant with higher HLB can result
in preparation of SLNs with larger size [53]. Additionally, as the surfactant concentration
elevated from 1% to 1.5%, the particle size of SLNs decreased. This might be assigned
to reduction within interfacial tension between the emulsion phases by increasing the
concentration of surfactant which led to smaller PS of SLNs after congealing [50,52].
Moving towards the final parameter, The ZP of all prepared drug-SLNs was ranged
from −12.3 ± 0.77 mV for F1 to −39.4 ± 0.095 mV for F6. zeta potential (ZP) is defined as
potential difference existing within the stationary layer between the dispersion medium
and the dispersed phase (solid particles) [54]. The value of ZP provides indication for the
preparation stability, where higher values correlate to higher formulation stability [55].
Within the presented model Equation (3), the ZP of prepared drug-SLNs increased by
increasing the level of lipid and surfactant types yet decreased by increasing the level of
surfactant concentration.
Y3 (ZP) = 25.79 + 9.79 X1 + 0.4375 X2 − 1.44 X3

(3)

Corresponding 3D-response surface plot showed the effect factors on ZP responses
(Figure 14). The type of lipid had a significant impact on negative value of ZP. The value
was increased by using GMS than in case of COMP which might be related to longer
carbon-chain of GMS resulted in the larger size of SLNs and larger surface area. It was
found that negative zeta potential of the prepared SLNs was slightly decreased by using
Cremophor RH40 while increased in case of Poloxamer 188 which may be attributed to
differences within respective HLB values [56]. Moreover, ZP was decreased with increased
surfactant concentration which may be due to the masking of surface charge by increasing
the surfactant concentration [50,57]. It worth mentioning that the PDI values of all prepared
drug-SLNs ranged from 0.282 ± 0.01 to 0.639 ± 0.12 for F2 and F8, respectively. Findings
from PDI values indicated a narrow size distribution [54].
2.5.3. Optimization of Formulation Variables to Select the Best Formula
Purpose of optimization was to maximize EE%, minimize PS, as well as maximize
values of the ZP. The Design-Expert V.11 software was used for obtaining an optimum
level of each single formulation factor to achieve the desired goals for every response
and obtain the optimized formulation of drug-SLNs. According to 23 -factorial design,
formulation F8 was the optimized formulation in which prepared using GMS as a solid
lipid and poloxamer 188 as a surfactant in concentration 1.5%. The predicted values of
responses for the optimized formulation were 95.325% for EE% (Y1), 284.075 nm for PS
(Y2), and −34.575 mV for ZP (Y3). Interestingly, these predicted values were close to
the actual values of responses with desirability value 0.781 which indicate the validity of
23 -factorial design. The transmission electron microscopic (TEM) image of F8 illustrated
the spherical shape of the prepared SLNs within the nano size (Figure 15A). Size analysis
for TEM image, using Nano-Measurer® V.1.2 software (Shanghai, China), exhibited narrow
size distribution (Figure 15B). These findings were in good agreement with Qushawy et al.
preparing carbamazepine-SLNs using GMS and stearic acid where the prepared SLNs were
spherical in shape with nano size [44].
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sponses for the optimized formulation were 95.325% for EE% (Y1), 284.075 nm for PS
(Y2), and −34.575 mV for ZP (Y3). Interestingly, these predicted values were close to the
actual values of responses with desirability value 0.781 which indicate the validity of
23-factorial design. The transmission electron microscopic (TEM) image of F8 illustrated
the spherical shape of the prepared SLNs within the nano size (Figure 15A). Size analysis
24 of 37
for TEM image, using Nano-Measurer® V.1.2 software (Shanghai, China), exhibited narrow size distribution (Figure 15B). These findings were in good agreement with
Qushawy et al. preparing carbamazepine-SLNs using GMS and stearic acid where the
prepared SLNs were spherical in shape with nano size [44].
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Based on the fact that 8b is lipophilic (Consensus LogPo/w = 5.16) with poor aqueous solubility, it was predicted to possess low bioavailability [60]. Incorporation of the drug into
lipid-based nanoparticles might offer significant improvement in its anticancer efficacy
as the lipid nature of the SLN increases its solubility and allows the presence of the drug
in its amorphous form. The latter might cause an increase within the drug 8b penetration

2.5.5. Cytotoxicity Study of Optimized Formulation

Pharmaceuticals 2021, 14, 113

The cytotoxic efficacy of compound 8b was assayed in its pure form and in optimized SLN formulation (F8). From the Sulforhodamine B (SRB) assay, the compound’s
25 of 37
IC50 within MDA-MB-231/breast cancer cell line was significantly decreased from 12.43
±
0.50 µM to 9.27 ± 0.34 µM for 8b and formulated form, respectively (p < 0.05) (Figure 17).
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3. Materials and Methods
3.1. General Experimental
All chemicals, reagents and solvents were purchased from Sigma-Aldrich, Fisher
Scientific, Alfa-Aesar, Fluka and Acros Chemicals. Whenever required, solvents were
dried prior to use as described by the handbook Purification of Laboratory Chemicals
and stored over 4Å molecular sieves under nitrogen. Flash column chromatography
was performed with silica gel (230–400 mesh) (Merck) and TLC was performed on precoated silica gel plates (Merck Kiesel gel 60F254, BDH). Melting points were determined
on an electrothermal instrument (Gallenkamp) and are uncorrected. Compounds were
visualized by irradiation with UV light at 254 nm and 365 nm. The NMR spectra of all
new compounds were recorded on a Bruker AVANCE DPX500 spectrometer operating at
500 and 125 MHz for 1 H and 13 C NMR, respectively, and auto calibrated to the deuterated
solvent reference peak (Supplementary Materials; Figure S2). Chemical shifts are given in
δ relative to tetramethylsilane (TMS); the coupling constants (J) are given in Hertz. TMS
was used as an internal standard (δ = 0 ppm) for 1 H NMR and CDCl3 served as an internal
standard (δ = 77.0 ppm) for 13 C NMR. Multiplicity is denoted as s (singlet), d (doublet),
t (triplet), q (quartet), m (multiplet) or combinations thereof. The compounds imines
11a–f and aldehydes 12a–f were prepared according to Kishk et al. [29]. The DI Analysis
Shimadzu QP2010-Plus® GC/MS (ShimadzuTM , Tokyo, Japan) was adopted for recording
the low-resolution mass spectra (MS) of the synthesized compounds at electron impact
(EI+ ) mode. Regarding purity analysis, the elemental analyses were recorded on Vario®
EL-CHNS Elemental Analyzer (GmbHTM , Hanau, Germany). The results of elemental
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analyses (C, H, N) were found to be in good agreement (±0.45%) with the calculated values.
All compounds were >95% pure.
3.2. Chemical Synthesis
3.2.1. Synthesis of 2-(chloromethyl)-1H-Benzimidazole (2)
A mixture of ortho-phenylene diamine (1.0 g, 9.25 mmol) and chloroacetic acid (1.32 g,
13.97 mmol) in 4 N HCl (60 mL) was refluxed for 24 h. The purified product was obtained by
re-crystallization from water after neutralization with 6 N NH4 OH, yield 0.4 g (40%). The
product was used in the following step without further purification [63]. M.p. 149–151 ◦ C
(Lit. 147.8–148.2 ◦ C). 1 H NMR (DMSO-d6 ): δ 4.91 (s, 2H, CH2 ), 7.25–7.29 (m, 2H, CH, Ar),
and 7.57–7.59 (m, 2H, CH, Ar).
3.2.2. Synthesis of 2-Aminomethyl-Benzimidazole Derivatives (3a–d)
A mixture of compound (2) (1 mmol) and the appropriate aromatic amine (1 mmol) in
the presence of potassium iodide (1 mmol) were refluxed in absolute ethanol for 6 h, then
potassium iodide (1 mmol) dissolved in 5 mL water was added and refluxed overnight.
After cooling to room temperature, the solution was poured into ice, filtered and crude product was purified by flash column chromatography using gradient EtOAc: n-hexane [26].
N-((1H-benzo[d]imidazol-2-yl)methyl)-3-methylaniline (3a).
Prepared from 3-methylaniline, yield 0.07 g (71%), as an off-white powder. M.p.
139–141 ◦ C. TLC (EtOAc: n-Hexane 2:3), Rf : 0.23. 1 H NMR (DMSO-d6 ): δ 2.39 (m, 3H,
CH3 ), 4.46 (d, J = 5.38 Hz, 2H, CH2 ), 6.17 (t, J = 7.2 Hz, 1H, NH), 6.50 (s, 1H, NH), 6.96
(s, 1H, CH, Ar), 7.28 (d, J = 7.2 Hz, 2H, CH, Ar), 7.49 (m, 1H, CH, Ar), 7.56 (t, J = 7.4 Hz,
2H, CH, Ar), 7.76 (d, J = 7.4 Hz, 2H, CH, Ar). 13 C NMR (DMSO-d6 ): δ 21.79 (CH3 ), 42.29
(CH2 ), 110 (2 × CH, Ar), 113.6 (2 × CH, Ar), 117.8 (CH, Ar), 129.2 (2 × CH, Ar), 129.75 (CH,
Ar), 138.34 (3C, Ar), 143.4 (C, Ar). MS (EI+ ) m/z: 237.38 [M+ ]. Anal. Calcd for C15 H15 N3
(237.31): C, 75.92; H, 6.38; N, 17.72. Found: C, 75.81; H, 6.22; N, 17.60
N-((1H-benzo[d]imidazol-2-yl)methyl)-2,6-dimethylaniline (3b).
Prepared from 3,5-dimethylaniline, yield 0.06 g (61%), as an off-white powder. M.p.
159–161 ◦ C. TLC (EtOAc: n-Hexane 1:2), Rf : 0.5. 1 H NMR (DMSO-d6 ): δ 2.30 (m, 6H, 2 × CH3 ),
4.36 (s, 2H, CH2 ), 4.54 (s, 1H, NH), 6.81–6.89 (m, 1H, Ar), 6.94 (d, J = 7.34 Hz, 2H, Ar), 7.16–7.19
(m, 2H, Ar), 7.54 (d, J = 7.5 Hz, 2H, Ar). 13 C NMR (DMSO-d6 ): δ 18.9 (2 × CH3 ), 46.2 (CH2 ),
111.8 (2 × CH, Ar), 118.8 (CH, Ar), 122 (2 × CH, Ar), 129.3 (2 × CH, Ar), 129.6 (2C, Ar), 138.8
(2C, Ar), 146.1 (C, Ar), 154.4 (C, Ar). MS (EI+ ) m/z: 251.17 [M+ ]. Anal. Calcd for C16 H17 N3
(251.33): C, 76.46; H, 6.82; N, 16.72. Found: C, 76.37; H, 6.89; N, 16.73.
N-((1H-benzo[d]imidazol-2-yl)methyl)-3-bromoaniline (3c) [64].
Prepared from 3-bromoaniline, yield 0.07 g (73%), as a light brown powder. M.p.
139–141 ◦ C. TLC (EtOAc: n-hexane 1:2), Rf 0.27. 1 H NMR (DMSO-d6 ): δ 4.16 (s, 2H, CH2 ),
7.21–7.24 (m, 2H, Ar), 7.57 (d, J = 7.4 Hz, 2H, Ar), 7.59 (s, 1H, NH), 7.75 (d, J = 7.5 Hz, 1H,
Ar), 7.91–8.12 (m, 3H, Ar). 13 C NMR (DMSO-d6 ): δ 41.9 (CH2 ), 111.7 (2 × CH, Ar), 115.1
(2 × CH, Ar), 119.1 (CH, Ar), 121.8 (CH, Ar), 122.7 (2 × CH, Ar), 131.1 (1C, Ar), 150.5 (2C,
Ar), 153.5 (1C, Ar), 169. (1C, Ar). MS (EI+ ) m/z: 302.72 [M+ ]. Anal. Calcd for C14 H12 BrN3
(302.18): C, 55.65; H, 4.01; N, 13.92. Found: C, 55.62; H, 3.93; N, 13.51.
4-(((1H-benzo[d]imidazol-2-yl)methyl)amino)phenol (3d).
Prepared from 4-hydroxyaniline, yield 0.05 g (51%), as a brown powder. M.p.139–141 ◦ C.
TLC (EtOAc: n-hexane 1:2), Rf 0.4. 1 H NMR (DMSO-d6 ): δ 4.14 (s, 2H, CH2 ), 7.22 (d, J = 7.5 Hz,
2H, Ar), 7.32 (d, J = 7.4 Hz, 2H, Ar), 7.47–7.49 (m, 1H, CH, Ar), 7.57 (d, J = 7.5 Hz, 2H, Ar),
7.59 (s, 1H, NH), 7.75 (d, J = 7.5 Hz, 1H, Ar), 9.45 (s, 1H, OH), 12.18 (s, 1H, NH-indole). 13 C
NMR (DMSO-d6 ): δ 43.6 (CH2 ), 115.2 (2 × CH, Ar), 116.3 (2 × CH, Ar), 116.7 (2 × CH, Ar),
124.1 (2 × CH, Ar), 139.1 (2C, Ar), 141.5 (1C, Ar), 142.1 (1C, Ar), 146.9 (1C, Ar). MS (EI+ ) m/z:
239.11 [M+ ]. Anal. Calcd for C14 H13 N3 O (239.28): C, 70.28; H, 5.48; N, 17.56. Found: C, 70.29;
H, 5.49; N, 17.45.
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3.2.3. Synthesis of Ethyl, 1H-Indole-2-Carboxylate (5)
To a stirred solution of 1H-indole-2-carboxylic acid (4) (1.5 g, 9.31 mmol) in dry ethanol
(25 mL), sulfuric acid (0.5 mL) was added as catalyst. The reaction mixture was refluxed
for 1.5 h. After the reaction was complete, water (25 mL) was added, and the mixture
was extracted with ethyl acetate (3 × 50 mL). The combined organic phases were washed
with brine, water, and dried over anhydrous Na2 SO4 . The solvent was evaporated under
vacuum to give ethyl-1H-indole-2-carboxylate (6) as a white powder [65]. M.p. 126–127 ◦ C
(Lit. M.p. 123–124 ◦ C). 1 H NMR (CDCl3 ) δ 1.43 (t, J = 7.4 Hz, 3H, CH3 ), 4.51 (q, J = 7.2 Hz,
2H, CH2 ), 6.96–6.99 (m, 1H, Ar), 7.12 (d, J = 7.0 Hz, 2H, Ar), 7.35 (d, J = 7.2 Hz, 2H, Ar),
9.31 (s, 1H, NH).
3.2.4. Synthesis of 1H-Indole-2-Carbohydrazide (6)
To a stirred solution of ethyl 1H-indole-2-carboxylate (5) (0.46 g, 7.93 mmol) was added
hydrazine monohydrate (4 mL, 79.90 mmol) in the presence of 15 mL of absolute ethanol.
The reaction mixture was refluxed for 6 h. After the reaction was complete, the solution was
evaporated under vacuum, the remaining residue after evaporation (0.50 g) was washed with
dichloromethane (0.5 mL × 3). The product was obtained as colorless crystals and was used
directly in the following reaction without any further purifications [66]. M.p. 245–246 ◦ C (Lit.
M.p. 247–248 ◦ C), 1 H-NMR (DMSO-d6 ): δ 4.49 (s, 2H, NH2 ), 7.13 (d, J = 4.6 Hz, 1H, Ar), 7.19
(s, 1H, Ar), 7.25 (d, J = 7.4 Hz, 1H, Ar), 7.49 (d, J = 7.4 Hz, 1H, Ar), 7.65 (d, J = 7.5 Hz, 1H, Ar),
9.79 (s, 1H, NH), 11.68 (s, 1H, NH, indole).
3.2.5. Synthesis of Different Carbohydrazide Derivatives (7, 8)
Equimolar amount of appropriate aromatic aldehyde was added to a solution of the
hydrazide compound (6) (10 mmol) in absolute ethanol (5 mL), in presence of catalytic
amount of glacial acetic acid (0.4 mL). Reaction mixture was allowed to reflux with continuous stirring for about 1.5 h and poured into ice/water mixture. The precipitate was filtered,
washed with cold water and purified by flash column chromatography using gradient
elution of EtOAc: n-hexane to give the corresponding carbohydrazide [67–69].
N0 -benzylidene-1H-indole-2-carbohydrazide (7a) [67].
Prepared from benzaldehyde, yield 0.045 g (45%), as an off-white powder. M.p. 111–
113 ◦ C. TLC (EtOAc: n-Hexane 1:2), Rf : 0.40. 1 H NMR (DMSO-d6 ): δ 7.08 (d, J = 7.34 Hz,
2H, CH, Ar), 7.28 (s, 1H, CH, indole), 7.54–7.59 (m, 5H, CH, Ar), 7.78 (d, J = 6.11 Hz, 2H,
CH, Ar), 8.47 (s, 1H, CH=N), 11.76 (s, 1H, NH, indole), 11.92 (s, 1H, NH, amide). 13 C
NMR (DMSO-d6 ): δ 111.1 (CH, Ar), 114.9 (CH, Ar), 119.8 (CH, Ar), 120.7 (CH, Ar), 121.7
(CH, Ar), 128.8 (2 × CH, Ar), 129.3 (2 × CH, Ar), 131.3 (C, Ar), 133.7 (C, Ar), 138.5 (C, Ar),
139.8 (C, Ar), 146.8 (2 × CH, Ar), 157.6 (C=O). MS (EI+ ) m/z: 263.55 [M+ ]. Anal. Calcd for
C16 H13 N3 O (263.30): C, 72.99; H, 4.98; N, 15.96. Found: C, 72.92; H, 5.03; N, 16.14
N0 -(4-methoxybenzylidene)-1H-indole-2-carbohydrazide (7b) [69].
Prepared from 4-methoxybenzaldehyde, yield 0.03 g (30%), as an off-white powder.
M.p. 104–106 ◦ C (Lit. M.p. 98.9 ◦ C). TLC (EtOAc: n-Hexane 1:2), Rf : 0.35. 1 H NMR
(DMSO-d6 ): δ 4.33 (s, 3H, CH3 ), 7.18 (d, J = 7.33 Hz, 2H, CH, Ar), 7.29 (s, 1H, CH, indole),
7.56–7.63 (m, 5H, CH, Ar), 7.82 (d, J = 6.15 Hz, 2H, CH, Ar), 8.49 (s, 1H, CH=N), 11.79 (s,
1H, NH, indole), 11.97 (s, 1H, NH, amide). 13 C NMR (DMSO-d6 ): δ 55.3 (CH3 ), 111.3 (CH,
Ar), 115.2 (CH, Ar), 120.1 (CH, Ar), 120.8 (CH, Ar), 121.6 (CH, Ar), 129.1 (2 × CH, Ar), 129.5
(2 × CH, Ar), 131.7 (C, Ar), 133.5 (C, Ar), 138.4 (C, Ar), 140.1 (C, Ar), 146.5 (2 × CH, Ar),
157.4 (C=O). MS (EI+ ) m/z: 293.87 [M+ ]. Anal. Calcd for C17 H15 N3 O2 (293.30): C, 69.61; H,
5.15; N, 14.30. Found: C, 69.9; H, 5.11; N, 14.35
N0 -(4-(dimethylamino)benzylidene)-1H-indole-2-carbohydrazide (7c) [69].
Prepared from 4-(dimethylamino)benzaldehyde, yield 0.04 g (35%), as a yellow powder. M.p. 90–92 ◦ C (Lit. M.p. 82 ◦ C). TLC (EtOAc: n-Hexane 1:2), Rf : 0.35. 1 H NMR
(DMSO-d6 ): δ 3.05 (m, 6H, 2 × CH3 ), 6.77 (t, J = 7.33 Hz, 1H, CH, Ar), 7.07 (s, 1H, CH, indole), 7.19 (d, J = 7.34 Hz, 2H, CH, Ar), 7.24 (d, J = 7.34 Hz, 2H, CH, Ar), 7.55 (d, J = 7.35 Hz,
2H, CH, Ar), 7.63–7.65 (m, 1H, CH, Ar), 8.31 (s, 1H, CH=N), 11.64 (s, 1H, NH, indole), 11.82
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(s, 1H, NH, amide). 13 C NMR (DMSO-d6 ): δ 41.3 (2 × CH3 ), 103.1 (CH, Ar), 111.8 (2 × CH,
Ar), 112.3 (CH, Ar), 119.9 (CH, Ar), 121.6 (CH, Ar), 121.8 (CH, Ar), 123.6 (C, Ar), 127.1 (CH,
Ar), 128.4 (CH, Ar), 130.4 (C, Ar), 136.8 (2C, Ar), 148.1 (CH, Ar), 151.4 (C, Ar), 157.2 (C=O).
MS (EI+ ) m/z: 306.82 [M+ ]. Anal. Calcd for C18 H18 N4 O (306.37): C, 70.57; H, 5.92; N, 18.29.
Found: C, 70.51; H, 5.94; N, 17.91.
N0 -(pyridin-3-ylmethylene)-1H-indole-2-carbohydrazide (7d) [68].
Prepared from nicotinaldehyde, yield 0.03 g (29%), as an off-white powder. M.p.
252–254 ◦ C (Lit. M.p. 250–251 ◦ C). TLC (EtOAc: n-Hexane 1:2), Rf : 0.29. 1 H NMR (DMSOd6 ): δ 6.23 (t, J = 7.56 Hz, 2H, CH, Ar), 7.44–7.64 (m, 4H, CH, Ar), 7.33 (d, J = 7.56 Hz, 1H,
CH, Ar), 7.66 (s, 1H, CH, Ar), 7.78 (d, J = 7.44 Hz, 2H), 8.34 (s, 1H, CH=N), 11.66 (s, 1H,
NH, indole), 11.83 (s, 1H, NH, amide). 13 C NMR (DMSO-d6 ): δ 103.8 (CH, Ar), 112.4 (CH,
Ar), 120.1 (CH, Ar), 121.9 (CH, Ar), 124.1 (CH, Ar), 126.9 (CH, Ar), 129.8 (C, Ar), 130.2 (C,
Ar), 133.4 (CH, Ar), 136.9 (C, Ar), 144.3 (C, Ar), 148.7 (CH, Ar), 150.7 (2 × CH, Ar), 157.7
(C=O). MS (EI+ ) m/z: 264.75 [M+ ]. Anal. Calcd for C15 H12 N4 O (264.29): C, 68.17; H, 4.58;
N, 21.2. Found: C, 68.21; H, 4.55; N, 20.90.
N0 -((3-(4-ethylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indole-2- carbohydrazide (8a).
Prepared from 3-(4-ethylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (12a), yield
0.04 g (41%), as an off-white powder. M.p. 254–256 ◦ C. TLC (EtOAc: n-Hexane 1:1), Rf :
0.42. 1 H NMR (DMSO-d6 ): δ 1.24 (t, J = 7.56 Hz, 3H, CH3 ), 2.69 (q, J = 7.56 Hz, 2H, CH2 ),
6.23 (t, J = 7.22 Hz, 1H, Ar), 6.35 (t, 1H, Ar), 6.43 (s, 1H, Ar), 6.51–6.59 (m, 3H, CH, Ar), 6.71
(d, J = 8.25 Hz, 2H, CH, Ar), 6.89 (d, J = 7.56 Hz, 2H, CH, Ar), 6.95 (d, J = 8.25 Hz, 2H, CH,
Ar), 7.20 (d, J = 7.56 Hz, 2H, CH, Ar), 7.71 (s, 1H, CH, Ar), 8.33 (s, 1H, CH=N), 11.76 (s,
1H, NH, indole), 11.85 (s, 1H, NH, amide). 13 C NMR (DMSO-d6 ): δ 15.6 (CH3 ), 28.2 (CH2 ),
103.2 (CH, Ar), 112.3 (C, Ar), 116.8 (CH, Ar), 118.8 (2 × CH, Ar), 119.9 (CH, Ar), 121.7 (CH,
Ar), 123.7 (CH, Ar), 126.8 (2 × CH, Ar), 126.9 (CH, Ar), 128.2 (CH), 128.5 (CH, Ar), 129.4
(3 × CH, Ar), 129.6 (C, Ar), 130.2 (C, Ar), 136.7 (2C, Ar), 139.1 (CH, Ar), 140.4 (C, Ar), 144.3
(C, Ar), 152.1 (C, Ar), 157.3 (C=O). MS (EI+ ) m/z: 233.14 [M+ ]. Anal. Calcd for C27 H23 N5 O
(433.52): C, 74.81; H, 5.84; N, 15.35. Found: C, 74.85; H, 5.49; N, 15.24.
N0 -((1-phenyl-3-(4-propylphenyl)-1H-pyrazol-4-yl)methylene)-1H-indole-2- carbohydrazide (8b).
Prepared from 1-phenyl-3-(4-propylphenyl)-1H-pyrazole-4-carbaldehyde (12b), yield
0.04 g (39%), as an off-white powder. M.p. 219–221 ◦ C. TLC (EtOAc: n-Hexane 1:2), Rf :
0.51. 1 H NMR (DMSO-d6 ): δ 0.93 (t, J = 7.4 Hz, 3H, CH3 ), 1.65 (sext, J = 7.3 Hz, 2H, CH2 ),
2.63 (t, J = 7.4 Hz, 2H, CH2 ), 6.22 (t, J = 7.56 Hz, 1H, CH, Ar), 6.33 (t, J = 7.56 Hz, 1H, CH,
Ar), 6.44 (s, 1H, CH, Ar), 6.55–6.61 (m, 3H, CH, Ar), 6.69 (d, J = 8.25 Hz, 2H, CH, Ar), 6.75
(t, J = 7.90 Hz, 2H, CH, Ar), 6.81 (d, J = 8.25 Hz, 2H, CH, Ar), 7.19 (d, J = 7.56Hz, 2H, CH,
Ar), 7.73 (s, 1H, CH, Ar), 8.33 (s, 1H, CH=N), 11.76 (s, 1H, NH, indole), 11.85 (s, 1H, NH,
amide). 13 C NMR (DMSO-d6 ): δ 13.7 (CH3 ), 24.1 (CH2 ), 37.9 (CH2 ), 103.4 (CH, Ar), 112.5
(C, Ar), 116.8 (CH, Ar), 118.8 (2 × CH, Ar), 119.9 (CH, Ar), 121.7 (CH, Ar), 123.8 (CH, Ar),
126.8 (CH, Ar), 126.9 (CH, Ar), 127.1 (CH, Ar), 128.3 (CH), 128.7 (CH, Ar), 129.4 (2 × CH,
Ar), 129.5 (2 × CH, Ar), 130.2 (C, Ar), 137.8 (2C, Ar), 139.5 (C, Ar), 140.3 (C, Ar), 143.5 (C,
Ar), 152.5 (C, Ar), 156.5 (C=O). MS (EI+ ) m/z: 447.79 [M+ ]. Anal. Calcd for C28 H25 N5 O
(447.54): C, 75.15; H, 5.63; N, 15.65. Found: C, 75.11; H, 5.89; N, 15.64.
N0 -((3-(4-isopropylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indole-2- carbohydrazide (8c).
Prepared from 3-(4-isopropylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (12c),
yield 0.03 g (39%), as an off-white powder. M.p. 219–221 ◦ C. TLC (EtOAc: n-Hexane
1:2), Rf : 0.52. 1 H NMR (DMSO-d6 ): δ 1.26 (d, J = 6.9 Hz, 6H, 2 × CH3 ), 2.97 (sept, J = 6.8 Hz,
1H, CH), 7.07 (t, J = 7.56 Hz, 1H, CH, Ar), 7.16 (t, J = 7.56 Hz, 1H, CH, Ar), 7.29 (s, 1H, CH,
Ar), 7.32–7.39 (m, 3H, CH, Ar), 7.43–7.52 (m, 3H, CH, Ar), 7.61 (d, J = 7.61 Hz, 2H, CH, Ar),
7.73 (d, J = 7.58 Hz, 2H, CH, Ar), 7.94 (d, J = 7.57 Hz, 2H, CH, Ar), 8.52 (s, 1H, CH, Ar), 8.64
(s, 1H, CH=N), 11.79 (s, 1H, NH, indole), 11.93 (s, 1H, NH, amide). 13 C NMR (DMSO-d6 ):
δ 23.8 (2 × CH3 ), 33.3 (CH), 103.7 (CH, Ar), 113.1 (C, Ar), 116.9 (CH, Ar), 118.8 (2 × CH,
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Ar), 119.9 (CH, Ar), 121.1 (CH, Ar), 123.7 (CH, Ar), 126.7 (2 × CH, Ar), 126.9 (2 × CH, Ar),
127.0 (2 × CH, Ar), 128.5 (2 × CH, Ar), 129.6 (C, Ar), 130.1 (C, Ar), 136.8 (2C, Ar), 139.1
(CH, Ar), 140.4 (C, Ar), 149.9 (C, Ar), 153.3 (C, Ar), 157.8 (C=O). MS (EI+ ) m/z: 447.45 [M+ ].
Anal. Calcd for C28 H25 N5 O (447.54): C, 75.15; H, 5.63; N, 15.65. Found: C, 75.11; H, 5.89;
N, 15.85.
N0 -((3-(4-isobutylphenyl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indole-2- carbohydrazide (8d).
Prepared from 3-(4-isobutylphenyl)-1-phenyl-1H-pyrazole-4-carbaldehyde (12d), yield
0.04 g (42%), as an off-white powder. M.p. 229–231 ◦ C. TLC (EtOAc: Hexane 1:2), Rf : 0.45.
1 H NMR (DMSO-d ): δ 0.88 (d, J = 6.7 Hz, 6H, 2 × CH ) 1.88 (m, 1 H, CH), 2.51 (d,
6
3
J = 6.8 Hz, 2H, CH2 ), 7.07 (t, J = 6.6 Hz, 1H, CH, Ar), 7.21 (t, J = 7.5 Hz, 1H, CH, Ar), 7.29 (s,
1H, CH, Ar), 7.35 (t, J = 6.9 Hz, 2H, CH, Ar), 7.49–7.56 (m, 2H, CH, Ar), 7.63 (d, J = 7.4 Hz,
2H, CH, Ar), 7.68–7.72 (m, 3H, CH, Ar), 8.03 (d, J = 7.5 Hz, 2H, CH, Ar), 8.53 (s, 1H, CH,
Ar), 8.69 (s, 1H, CH=N), 11.78 (s, 1H, NH, indole), 11.92 (s, 1H, NH, amide). 13 C NMR
(DMSO-d6 ): δ 22.1 (2 × CH3 ), 29.6 (CH), 44.3 (CH2 ), 103.2 (CH, Ar), 112.4 (C, Ar), 116.8
(CH, Ar), 118.8 (CH, Ar), 119.9 (CH, Ar), 121.7 (CH, Ar), 123.7 (2 × CH, Ar), 126.8 (CH,
Ar), 126.9 (CH, Ar), 127 (CH, Ar), 128.2 (CH, Ar), 129.4 (C, Ar), 129.5 (2 × CH, Ar), 129.6
(2 × CH, Ar), 130.1 (C, Ar), 136.8 (C, Ar), 139.1 (C, Ar), 141.3 (C, Ar), 141.8 (CH, Ar), 151.8
(2C, Ar), 157.2 (C=O). MS (EI+ ) m/z: 461 [M+ ]. Anal. Calcd for C29 H27 N5 O (461.57): C,
75.46; H, 5.90; N, 15.17. Found: C, 75.30; H, 6.11; N, 15.20.
N0 -((3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazol-4-yl)methylene)-1H-indole-2- carbohydrazide (8e).
Prepared from 3-(benzo[d][1,3]dioxol-5-yl)-1-phenyl-1H-pyrazole-4-carbaldehyde (12e),
yield 0.03 g (33%), as an off-white powder. M.p. 239–241 ◦ C. TLC (EtOAc: n-Hexane 1:2),
Rf : 0.35. 1 H NMR (DMSO-d6 ): δ 5.29 (s, 2H, CH2 ), 6.31–6.37 (m, 2H, CH, Ar), 6.49 (s, 1H,
CH, Ar), 6.57–6.62 (m, 3H, CH, Ar), 6.62 (d, J = 8.25 Hz, 1H, CH, Ar), 6.73 (d, J = 7.90 Hz,
4H, CH, Ar), 6.89 (d, J = 8.25 Hz, 1H, CH, Ar), 7.20 (s, 1H, CH, Ar), 7.71 (s, 1H, CH, Ar), 8.33
(s, 1H, CH=N), 11.76 (s, 1H, NH, indole), 11.85 (s, 1H, NH, amide). 13 C NMR (DMSO-d6 ):
δ 101.3 (CH2 ), 103.3 (CH, Ar), 108.6 (CH, Ar), 108.7 (CH, Ar), 112.3 (C, Ar), 116.7 (2 × CH,
Ar), 118.8 (C, Ar), 119.9 (CH, Ar), 121.7 (CH, Ar), 122.5 (CH, Ar), 123.7 (CH, Ar), 124.1 (CH,
Ar), 126.9 (2C, Ar), 127.2 (CH, Ar), 127.5 (CH, Ar), 130.2 (CH, Ar), 130.5 (CH, Ar), 136.8 (C,
Ar), 139.0 (C, Ar), 140.3 (CH, Ar), 147.6 (C, Ar), 147.7 (C, Ar), 151.6 (C, Ar), 157.2 (C=O).
MS (EI+ ) m/z: 449 [M+ ]. Anal. Calcd for C29 H27 N5 O (461.57): C, 69.48; H, 4.26; N, 15.58. It
was Found: H, 4.16; C, 69.03; N, 15.22.
N0 -((5-chloro-1-(3,4-dinitrophenyl)-3-methyl-1H-pyrazol-4-yl)methylene)-1H-indole-2carbohydrazide (8f).
Prepared from 5-chloro-1-(3,4-dinitrophenyl)-3-methyl-1H-pyrazole-4-carbaldehyde,
yield 0.04 g (37%), as an off-white powder. M.p. 204–206 ◦ C. TLC (EtOAc: n-Hexane 1:2),
Rf : 0.37. 1 H NMR (DMSO-d6 ): δ 1.65 (s, 3H, CH3 ), 6.24–6.26 (m, 2H, CH, Ar), 6.49 (s, 1H,
CH, Ar), 6.59 (d, J = 7.4 Hz, 2H, CH, Ar), 6.78 (d, J = 8.26 Hz, 2H, CH, Ar), 8.02 (s, 1H, CH,
Ar), 8.63 (s, 1H, CH=N), 11.76 (s, 1H, NH, indole), 11.85 (s, 1H, NH, amide). 13 C NMR
(DMSO-d6 ): δ 18.4 (CH3 ), 101.8 (CH, Ar), 103.1 (CH, Ar), 112.2 (CH, Ar), 112.3 (C, Ar), 119.6
(C, Ar), 119.8 (C, Ar), 121.3 (CH, Ar), 121.6 (CH, Ar), 123.0 (CH, Ar), 123.6 (CH, Ar), 127.0
(CH, Ar), 127.1 (CH, Ar), 130.1 (C, Ar), 130.4 (C, Ar), 136.2 (C, Ar), 136.6 (C, Ar), 147.7 (C,
Ar), 157.3 (C, Ar), 161.3 (C=O). MS (EI+ ) m/z: 467.79 [M+ ]. Anal. Calcd for C20 H14 ClN7 O5
(467.83): C, 51.35; H, 3.02; N, 20.96. Found: C, 51.34; H, 3.04; N, 20.91
3.3. MTT-Cell Proliferation Assay and Morphological Evaluation
Evaluating the cytotoxicity of tested compounds on two cancer cell lines (A549/lung
and MDA-MB-231/breast adenocarcinoma) and non-cancerous (MDCK/kidney cells) was
performed while adopting the formerly described method with small alterations [70]. Cancer
cell lines were propagated within Dulbecco’s Modified Eagle Medium-High Glucose (Cat.#:
P0103; DMEM_High Glucose with Na.Pyruvate and stable Glutamine, BiowestTM , Nuaillé,
France), while MDA-MB-231 cells were propagated within RPMI-1640 L-Glutamine medium
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(Cat.#:12-604F; Lonza-Verviers SPRLTM , Verviers, Belgium). The culturing media were
supplemented via 1% antibiotic-antimycotic 100X (Cat.#: L0010; BiowestTM , Nuaillé, France)
and 10% fetal bovine serum (FBS) (Cat.#: EU-000-H; SeralabTM , West Sussex, UK). Cells
were seeded as triplicates within 96-well plate, at 1 × 104 cells per well density, after being
counted and viability checked using the trypan blue staining solution (Cat.# ab233465;
AbcamTM , Cambridge, MA, USA). Seeded cells were permitted to adhere for 24 h under
5% CO2 and at 37 ◦ C incubating conditions. The assigned compounds were dissolved in
500 µL DMSO affording the stock solution (100 mM) being ready for more diluting within
the whole medium to obtain the compound’s final concentrations; 0.1, 1, 10, 100 µM for
cell treatments. Notably, the final DMSO-culture medium concentration was not allowed
to exceed 0.2% (v/v) [71]. Following 24 h compound-cell treatment, the medium was
substituted by fresh one and cells were permitted to develop for 48 h. At four hours
prior the end of incubation, 10 µL MTT Sigma-AldrichTM (5 mg/mL in PBS 1X without
magnesium and calcium; Cat.# 17-516F, Lonza-VerviersTM , Basel, Switzerland) were added
to all wells. Following the complete 48 h incubation, 100 µL DMSO was all added to all wells
where they were subsequently centrifuged at 4000 rpm for 5 min allowing the formazan
crystals of formazan to precipitate. Color was established and intensities were recorded at
490 nm using Synergy-Neo2® Hybrid MultiMode Plate Reader (BioTekTM , Winooski, VT,
USA), while subtracting the multi-well plates background absorbance at 690 nm. Percentage
cell viability was estimated using the subsequent formula: % cell-viability = (average
absorbance of treated wells/average absorbance of controls) × 100.
3.4. SRB Cytotoxicity Assay
MDA-MB-231: Breast Cancer cell line was obtained from NawahTM Scientific Inc.,
(Cairo, Egypt). Cells were maintained within DMEM provided by 100 units/mL of penicillin, 100 mg/mL streptomycin, and 10% of heat-inactivated FBS within 5% (v/v) CO2
humidified atmosphere (37 ◦ C). The validity of cell line was evaluated adopting the previously reported approach [72]. Briefly, an accurate volume (100 µL) of cell line suspension
(5 × 103 cells) was placed in 96-well plates and incubated for 24 h within complete media [73]. Cell line suspensions were then treated with another 100 µL media spiked with
various drug concentrations (0.01, 0.1, 1, 10, 100 µM/mL) and kept for 72 h. Then the
media were replaced with 150 µL of 10% trichloroacetic acid (TCA) for fixing cells through
subsequent 1 h incubation at 4 ◦ C [74]. Following incubation, TCA was removed, and cells
were washed via distilled water 5 times. Aliquots of 70 µL SRB solution (0.4% w/v; Cat.#
S1402; Sigma-AldrichTM , Taufkirchen, Germany) were added and cell were then incubated
in dark for 10 min at 25 ◦ C. Plates were subjected to triplicate washing via 1% acetic acid
and then permitted to be air-dried overnight [62]. Protein-bound SRB stain was extracted
by addition of tris base (150 µL, 10 mM) and the absorbance was measured at 540 nm using
FLUOstar-Omega® microplate reader (BMG-LabtechTM GmbH, Ortenberg, Germany) [75].
3.5. Morphological Evaluation
The impact of this tested final compounds on the morphology of treated MDA-MB231/breast cancer cell line was investigated, through planting cells within 6-well plates
and subsequently incubated with 0.1, 1, 10, 100 µM of 8b for 24 h. Variations within
the cells’ morphology were identified via Olympus® -CKX53 Inverted Metallurgical light
microscope (OlympusTM , Center Valley, PA, USA), snapped by Olympus® Digital Camera,
and analyzed by OLYMPUS® Stream image analysis software [76].
3.6. Flow Cytometer Analysis
Apoptotic assay and cell cycle analysis were proceeded according to previous literatures [77]. In brief, cells were planted in 1.0 × 106 cells/flask density for 24 h. Subsequently,
8b was added at its IC50 value and incubated for 48 h. Following incubation, MDA-MB-231
cells were trypsinized, harvested, and fixed according to information cited within Annexin®
V-FITC Detection Kit (Cat.#: K101-25, BioVisionTM , Milpitas, CA, USA), for quantifying
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cell’s DNA contents being treated with 8b relative to control sample using propidium
iodide stain (Cat.#: ab139418; AbcamTM , Cambridge, MA, USA). Finally, flow cytometry
analysis was done using BD-FACSCalibur® cell analyzer platform (Becton DickinsonBiosciences-SGTM , Singapore, Thailand) to estimate which cell cycle phase, the treated cells
would be arrested in, as well as computing the percentage of apoptotic cells.
3.7. DNA Fragmentation Assay
DNA isolation was performed through planting MDA-MB-231/breast cells at 0.16 × 106
density, prior to incubation at 37 ◦ C/humidified 5% CO2 overnight [78]. Following 48 h
exposure time, cells were harvested, washed and lysed via DNA-extraction buffer at
37 ◦ C overnight. The lysate was incubated after that with 100 µg/mL Micro-pestle®
DNase/RNase-free (Cat.#: 9097.1; Carl-RothTM , Karlsruhe, Germany) at 37 ◦ C for 2 h,
which was followed by three extraction processes using phenol:CHCl3 (1:1 v/v) (BiofluxTM ,
Selangor, Malaysia). A consequent re-extraction was done using CHCl3 and then the organic
solvent was centrifuged for 5 min at 12,000 rpm within 4 ◦ C conditions. Extracted DNA was
precipitated via ice-cold 3 M sodium acetate and absolute ethanol for 1 h at –20 ◦ C, which
was then proceeded through centrifugation (15 min—at 12,000 rpm—4 ◦ C). After washed
with 70% ethyl alcohol, DNA pellets were air-dried, dissolved within 40 µL Tris-HCl/EDTA
(pH 8.0), and then electrophoresed on 1.5% agarose gel for their final staining using ethidium bromide within Tris/acetate/EDTA buffer. DNA fragments were photographed using
GelDoc-Go® System (Bio-RadTM , Hercules, CA, USA).
3.8. Real-Time PCR Analysis
Quantitative Real-time PCR was operated on Rotor-Gene Q® PCR system as a reader
(Cat.#: 204774; QiagenTM , Milan, Italy) via GenElute® RNA extraction/SIGMA PCR kit
(Cat.#: REI10; QiagenTM , Milan, Italy)86 . Cells were treated with IC50 of 8b for 48 h and total
RNA was extracted from the non-treated and treated cells. RNA purity was assessed via
Nanodrop® 2000/2000c UV-Vis spectrophotometer (Thermo-ScientificTM , Bilbao, Spain).
Synthesis of cDNA was proceeded using QuantiNova® Reverse Transcription Kit (Cat.#:
RTN30; QiagenTM , Milan, Italy) and the subsequent PCR tests were conducted via single
tubes. Specific forward/reverse primer pairs were selected for investigated (Casp-3, -8, -9,
BAX, and Bcl2). Obtained results were expressed within Cycle threshold (Ct) values, while
relative quantitation of each measured gene was assessed based on ∆∆Ct calculations as
represented in Table 5 [79].
Table 5. Specific forward/reverse primer sequence of Casp-3, -8, -9, BAX and Bcl2.
Gene

Forward

Reverse

BAX
Casp-3
Casp-8
Casp-9
BcL-2

50 -AGTGGCAGCTGACATGTTTT-30

50 -GGAGGAAGTCCAATGTCCAG-30

50 -GGCCCTGAAATACGAAGTC-30
50 -GCCTCCCTCAAGTTCCT-30
50 -CGAACTAACAGGCAAGCAG-30
50 -CCTGTGGATGACTGAGTACC-30

50 -GGCAGTAGTCGACTCTGAAG-30
50 -CCTGGAGTCTCTGGAATAACA-30
50 -ACCTCACCAAATCCTCCAGAAC-30
50 -GAGACAGCCAGGAGAAATCA-30

3.9. ELISA Assay
Quantikine® Colorimetric Sandwich-ELISA Kit (Cat.#: DCTC0; R&D Systems, Minneapolis, MN, USA) was used for quantitating the targeted human cytochrome c protein
through immunoassay protocol [80]. Based on manufacturer’s instructions, MDA-MB231/breast cancer cells were incubated with 8b at its approximated IC50 , for 48 h. Following
incubation, both non-treated and treated cells were subjected to lysis via cell extraction
buffer. Lysates were then diluted by standard diluent buffer over the assay range, and then
estimated for human cytochrome-c protein.

Pharmaceuticals 2021, 14, 113

32 of 37

3.10. Molecular Docking Studies
Molecular docking experiments were performed on the 14 investigated using Molecular Operating Environment (MOE) software as reported in previous work with few
modifications [81–83]. In brief, ligands were constructed via the MOE “builder” tool,
and then proceeded through the minimization step, adopting MMFF94x forcefield and
2000 steps of conjugate-gradient approach till a gradient of 0.001 Kcal/Å was reached
0.1 RMS Kcal/mol/Å2 . The atomic structure of the target protein was prepared by the
MOE through 3D-protonation, at physiological pH (7), temperature of 300 K, and 0.1 mol/L
salt within implicit solvent at Generalized-Born/Volumn-Integral implicit solvent model.
Moreover, the protein was auto-corrected for partial charges, types of atoms, and bond
connectivity [11]. The adopted protocol was proceeded through the rigid receptor docking approach since the RMSD of the superimposed apo (PDB ID: 1g5m) and complexed
states of Bcl-2 (PDB ID: 6qgk) showed RMSD of 0.934 Å. Thus, ligand binding would
suggest non-significant impact on the protein conformational change either on local or
global aspects. Throughout the adopted docking protocol, the ligand conformations were
developed through the method of bond rotation, lodged within in the defined active site
guided by triangular-matching approach, and then conformations were ranked via the
London_dG scores. The top ten docked poses were retained for subsequent refinement
and then an energy minimization stage, within the target pocket, before they were rescored
using GBVI/WSA forcefield [84]. High docking energy, RMSD values (2.0 Å threshold),
and ligand interaction with relevant pocket residues, all were considered for selecting the
best docking pose for each investigated ligand. Analysis and visual inspection of ligandprotein interactions was achieved using PyMol v2.0.6 Graphics System (SchrödingerTM ,
NY, USA) [85]. The hydrophobic interactions were determined via MOE ligand interactions
tool as well as manual measurements using PyMol bond distance measurement tools.
3.11. Preparation of Drug-Loaded SLNs
Eight formulations of drug-SLNs were successfully prepared by the hot melting homogenization technique [48,61]. An accurate amount (450 mg) of selected lipid; either
COMP (Cat.#: 3123; GattefosséTM , Lyon, France) or GMS (Cat.#: 23A70; SasolTM , Hamburg,
Germany), was melted in a small glass vial at temperature 80 ◦ C which exceed the melting
point of both lipid. Consequently, 10 mg of drug was added and dissolved completely
forming oily phase. Considering the aqueous phase, it was prepared via addition of accurate amount of surfactant (COMP or Poloxamer 188; Cat.#: 9003-11-6; Sigma-AldrichTM ,
St. Louis, MO, USA) to distilled water and allowed to heat at the same temperature of
oily phase. Subsequently, aqueous phase was added slowly to oily phase with stirring
while keeping the temperature to yield coarse emulsion using a hot plate with stirrer
(Brandstead/ThermolyneTM , Ramsey, MN, USA). The resultant preparation was homogenized at 15,000 rpm for 15 min to form fine o/w emulsion using Heidolph® silent crusher
homogenizer (HeidolphTM , Schwabach, Germany) [86]. The final preparation was allowed
to cool at r.t. to solidify the SLNs the stored at refrigerator for further study.
3.12. HPLC Analysis
Drug stock solution of 1 mg/mL in mobile phase:Buffer (0.1% Triflouroacetic acid/water)
and acetonitrile was prepared, and seven dilutions were prepared in concentrations of 5,
10, 25, 50, 100, 200, and 300 µg/mL. All solutions were filtered using 0.22 µm syringe
filter and then 10 µl was subjected to HPLC analysis using Waters-2690 Alliance® HPLC
system (WatersTM , Milford, MA, USA) [87]. Peak area of drug was noted at 254 nm. Each
experiment was performed within a triplicate manner and mean peak area was plotted
against the drug concentration.
3.13. Determination of the Drug-SLNs Parameters (Y1–3)
For estimating the encapsulation efficiency (EE%; Y1), samples of the eight formulations of drug-SLNs were subjected to vortexing for 1 min followed by centrifugation
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at 15,000 rpm for 30 min using Biofuge® centrifuge (Primo-HeraeusTM , Germany) [61].
For each sample, the clear supernatant collected and filtered using 0.22 µm syringe filter
then 10 µl of each sample was injected and subjected to HPLC analysis at 254 nm [62].
Equation (4) was used to calculate the EE% of drug [62,88]. Dynamic light scattering (DLS)
technique was applied to determine PS (Y2), ZP (Y3), and PDI of all prepared drug-SLNs
using Zetasizer® (MalvernTM Instruments Ltd., Malvern, UK) [86]. The measurements
were done at 25 ◦ C after appropriate dilution of each sample [49].
EE% = (Total amount of drug-Unentrapped amount of drug)/(Total amount of drug) × 100

(4)

3.14. Surface Morphology of Optimized Formulation
Morphology of optimized formulation was determined by JTEM® transmission electron microscope (TEM; model 1010, JEOL® , Tokyo, Japan). A small sample of optimized
formulation was spread upon collodion-coated copper grid then left to be dried for nearly
2 min allowing the SLNs-collodion adherence [74,89]. The samples were subjected to
stain by addition of one drop of uranyl acetate solution. Following drying, samples were
examined with TEM.
3.15. In-Vitro Release Study of the Optimized Formulation
The in-vitro drug-release behavior of SLNs was determined through the dialysis
method [58]. The release of drug from SLNs was done using phosphate buffer saline
(pH 7.4) as dissolution medium. An accurate amount of SLNs (equivalent to 5 mg drug)
was taken and placed within the dialysis bag (MWCO: 12 kDa). The dialysis bag was
closed from both ends and placed within 75 mL Phosphate Buffer Saline (pH 7.4) as
dissolution medium. The analysis was conducted while maintaining the dissolution
medium at 37 ± 1 ◦ C and being stirred via magnetic stirrer at 100 rpm. Dissolution medium
samples (2 mL) were withdrawn at pre-determined time intervals (0.5, 1, 2, 4, 8, 12, 24 and
48 h). Equal volumes of fresh dissolution medium were added to replace the withdrawn
volumes for keeping sink condition [90]. The experiment was done in triplicate and the
amount of drug release was measured following the same procedure as in the entrapment
efficiency section.
4. Conclusions
The presented manuscript reported indole- and benzimidazole-based compounds
with promising pro-apoptotic activity targeting the Bcl-2 biological targets. The furnished
synthesized compounds owned structural diversity and chemical scaffolds that mimic
the market released Bcl-2 family pan-antagonist, obatoclax. Either through replacing the
pyrrole ring of obatoclax with benzimidazole or extending the structure after the indole
ring, fourteen compounds were afforded belonging to three chemical series. Biological
evaluation through MTT-proliferation on two solid tumor cell lines, A549/lung and MDAMB-231/breast adenocarcinoma, provided solid evidence concerning the compounds’
cytotoxic activity. Compound 8b was considered promising for further evaluation as it
possessed impressive balanced cytotoxic/safety profile on non-cancerous MDCK/kidney
cell line. Further, cell cycle analysis, DNA fragmentation, apoptotic gene expression, and
protein level analysis have confirmed the compound’s promising anti-cancer activity and
provided valuable insights regarding its molecular mechanisms. Moreover, a validated
molecular docking investigation, on Bcl-2 crystallized protein, has thoroughly investigated
the differential compounds’ bindings at the active site, while showing good correlation between the IC50 values and furnished docking scores. Finally, the introduction of compound
8b within a well-optimized solid lipid nanoparticle formulation has improved the compound’s pharmaceutical profile leading to a significant improvement at the compound’s
cytotoxic activity. All the above findings have introduced 8b as a promising anti-cancer
lead candidate that is worthy of future fine-tuned lead optimization and development
studies and exploration of its potentiality through in-vivo preclinical investigation.
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